152 related articles for article (PubMed ID: 22361937)
1. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript.
Bech PR; Ramachandran R; Dhillo WS; Martin NM; Bloom SR
Clin Chem; 2012 May; 58(5):941-3. PubMed ID: 22361937
[No Abstract] [Full Text] [Related]
2. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
3. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.
Miki M; Ito T; Hijioka M; Lee L; Yasunaga K; Ueda K; Fujiyama T; Tachibana Y; Kawabe K; Jensen RT; Ogawa Y
Jpn J Clin Oncol; 2017 Jun; 47(6):520-528. PubMed ID: 28334992
[TBL] [Abstract][Full Text] [Related]
4. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
Bech PR; Martin NM; Ramachandran R; Bloom SR
Ann Clin Biochem; 2014 Jan; 51(Pt 1):8-21. PubMed ID: 23939195
[TBL] [Abstract][Full Text] [Related]
5. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
Lyubimova NV; Churikova TK; Kushlinskii NE
Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
[TBL] [Abstract][Full Text] [Related]
7. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
8. Commentary to "chromogranin a: biological function and clinical utility in neuroendocrine tumor disease".
Jeske W; Glinicki P; Kapuścińska R
Ann Surg Oncol; 2011 Jan; 18(1):293. PubMed ID: 20549561
[No Abstract] [Full Text] [Related]
9. Analytical evaluation of a second generation assay for chromogranin A; a dual-site study.
Krabbe JG; Monaghan PJ; Russell J; de Rijke YB
Clin Chem Lab Med; 2016 Apr; 54(4):e139-42. PubMed ID: 26393331
[No Abstract] [Full Text] [Related]
10. Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy.
Bech P; Winstanley V; Murphy KG; Sam AH; Meeran K; Ghatei MA; Bloom SR
J Clin Endocrinol Metab; 2008 Apr; 93(4):1246-53. PubMed ID: 18211969
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ
Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254
[TBL] [Abstract][Full Text] [Related]
12. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
Glinicki P; Jeske W
Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
[TBL] [Abstract][Full Text] [Related]
13. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
14. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Dittadi R; Gion M
Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
[No Abstract] [Full Text] [Related]
15. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an ELISA method for the measurement of chromogranin A and comparison with an immunoradiometric method.
Dittadi R; Bertoli I
Int J Biol Markers; 2013 Apr; 28(1):114-6. PubMed ID: 23015397
[No Abstract] [Full Text] [Related]
18. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A in human disease.
O'Connor DT; Mahata SK; Taupenot L; Mahata M; Livsey Taylor CV; Kailasam MT; Ziegler MG; Parmer RJ
Adv Exp Med Biol; 2000; 482():377-88. PubMed ID: 11192598
[No Abstract] [Full Text] [Related]
20. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
Modlin IM; Gustafsson BI; Moss SF; Pavel M; Tsolakis AV; Kidd M
Ann Surg Oncol; 2010 Sep; 17(9):2427-43. PubMed ID: 20217257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
